Sumo Logic (SUMO) 10-Q 8 Dec 20 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Oct. 31, 2020	Nov. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 31, 2020
Document Transition Report	false
Entity File Number	001-39502
Entity Registrant Name	Sumo Logic, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-2234444
Entity Address, Address Line One	305 Main Street
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94063
City Area Code	650
Local Phone Number	810-8700
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	SUMO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		102,318,468
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001643269
Current Fiscal Year End Date	--01-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Oct. 31, 2020	Jan. 31, 2020
Current assets:
Cash and cash equivalents	$ 407,469	$ 101,513
Accounts receivable, net	41,685	27,011
Prepaid expenses	8,581	6,305
Deferred sales commissions, current	11,317	8,884
Other current assets	2,153	1,604
Total current assets	471,205	145,317
Property and equipment, net	3,952	2,993
Goodwill	50,672	50,672
Acquired intangible assets, net	12,298	17,415
Deferred sales commissions, noncurrent	24,605	17,479
Other noncurrent assets	840	3,885
Total assets	563,572	237,761
Current liabilities:
Accounts payable	8,678	6,151
Accrued expenses and other current liabilities	21,334	20,371
Deferred revenue, current	88,612	85,715
Total current liabilities	118,624	112,237
Deferred revenue, noncurrent	1,768	2,970
Redeemable convertible preferred stock warrant liability	0	270
Other noncurrent liabilities	4,883	2,691
Total liabilities	125,275	118,168
Commitments and contingencies (Note 7)
Redeemable convertible preferred stock	0	340,167
Stockholders’ equity (deficit):
Common stock	10	2
Additional paid-in-capital	815,735	97,131
Accumulated other comprehensive loss	(246)	(213)
Accumulated deficit	(377,202)	(317,494)
Total stockholders’ equity (deficit)	438,297	(220,574)
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)	$ 563,572	$ 237,761

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Income Statement [Abstract]
Revenue	$ 51,868	$ 40,513	$ 148,485	$ 110,745
Cost of revenue	13,601	11,212	42,140	29,151
Gross profit	38,267	29,301	106,345	81,594
Operating expenses:
Research and development	18,753	14,029	51,756	35,394
Sales and marketing	26,904	30,382	80,534	76,868
General and administrative	15,507	14,193	32,096	28,141
Total operating expenses	61,164	58,604	164,386	140,403
Loss from operations	(22,897)	(29,303)	(58,041)	(58,809)
Interest and other (expense) income, net	(322)	726	(249)	1,611
Interest expense	(290)	(40)	(654)	(66)
Loss before provision for income taxes	(23,509)	(28,617)	(58,944)	(57,264)
Provision for income taxes	417	2	764	357
Provision for income taxes	$ (23,926)	$ (28,619)	$ (59,708)	$ (57,621)
Net loss per share, basic and diluted (in USD per share)	$ (0.43)	$ (1.95)	$ (1.92)	$ (4.13)
Weighted-average number of shares outstanding, basic and diluted (in shares)	55,816	14,650	31,044	13,953

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (23,926)	$ (28,619)	$ (59,708)	$ (57,621)
Other comprehensive income (loss):
Foreign currency translation adjustments	(51)	97	(33)	(45)
Total comprehensive loss	$ (23,977)	$ (28,522)	$ (59,741)	$ (57,666)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Jan. 31, 2019	$ (202,464)	$ 1	$ 22,989	$ (97)	$ (225,357)
Beginning balance (in shares) at Jan. 31, 2019		13,065,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options	2,455	$ 0	2,455
Issuance of common stock upon exercise of stock options (in shares)		1,574,000
Issuance of common stock upon early exercise of stock options	0	$ 0
Issuance of common stock upon early exercise of stock options (in shares)		349,000
Vesting of early exercised stock options	132		132
Common stock issued in connection with acquisitions	43,873	$ 1	43,872
Common stock issued in connection with acquisitions (in shares)		2,922,000
Stock-based compensation	16,965		16,965
Foreign currency translation adjustments	(45)			(45)
Net loss	(57,621)				(57,621)
Ending balance at Oct. 31, 2019	(196,705)	$ 2	86,413	(142)	(282,978)
Ending balance (in shares) at Oct. 31, 2019		17,910,000
Beginning balance at Jan. 31, 2019	$ 234,095
Beginning balance (in shares) at Jan. 31, 2019	53,776,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series G redeemable convertible preferred stock, net issuance of costs of $3,927	$ 106,072
Issuance of Series G redeemable convertible preferred stock, net of issuance costs of $3,927 (in shares)	9,986,000
Ending balance (in shares) at Oct. 31, 2019	63,762,000
Ending balance at Oct. 31, 2019	$ 340,167
Beginning balance at Jul. 31, 2019	(223,200)	$ 1	31,397	(239)	(254,359)
Beginning balance (in shares) at Jul. 31, 2019		14,290,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options	1,186	$ 0	1,186
Issuance of common stock upon exercise of stock options (in shares)		698,000
Vesting of early exercised stock options	49		49
Common stock issued in connection with acquisitions	43,873	$ 1	43,872
Common stock issued in connection with acquisitions (in shares)		2,922,000
Stock-based compensation	9,909		9,909
Foreign currency translation adjustments	97			97
Net loss	(28,619)				(28,619)
Ending balance at Oct. 31, 2019	(196,705)	$ 2	86,413	(142)	(282,978)
Ending balance (in shares) at Oct. 31, 2019		17,910,000
Beginning balance at Jul. 31, 2019	$ 340,167
Beginning balance (in shares) at Jul. 31, 2019	63,762,000
Ending balance (in shares) at Oct. 31, 2019	63,762,000
Ending balance at Oct. 31, 2019	$ 340,167
Beginning balance at Jan. 31, 2020	(220,574)	$ 2	97,131	(213)	(317,494)
Beginning balance (in shares) at Jan. 31, 2020		18,984,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon initial public offering, net of underwriting discounts and issuance costs	342,685	$ 2	342,683
Issuance of common stock upon initial public offering, net of underwriting discounts and issuance costs (in shares)		17,020,000
Conversion of convertible redeemable preferred stock to common stock upon initial public offering	340,167	$ 6	340,161
Conversion of convertible redeemable preferred stock to common stock upon initial public stock offering (in shares)		63,762,000
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital upon initial public offering	512		512
Issuance of common stock upon exercise of stock options	6,113	$ 0	6,113
Issuance of common stock upon exercise of stock options (in shares)		2,222,000
Vesting of early exercised stock options	148		148
Common stock issued in connection with acquisitions	0	$ 0
Common stock issued in connection with acquisitions (in shares)		256,000
Stock-based compensation	28,987		28,987
Foreign currency translation adjustments	(33)			(33)
Net loss	(59,708)				(59,708)
Ending balance at Oct. 31, 2020	438,297	$ 10	815,735	(246)	(377,202)
Ending balance (in shares) at Oct. 31, 2020		102,244,000
Beginning balance at Jan. 31, 2020	$ 340,167
Beginning balance (in shares) at Jan. 31, 2020	63,762,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Conversion of convertible redeemable preferred stock to common stock upon initial public offering	$ (340,167)
Conversion of convertible redeemable preferred stock to common stock upon initial public offering (in shares)	(63,762,000)
Ending balance (in shares) at Oct. 31, 2020	0
Ending balance at Oct. 31, 2020	$ 0
Beginning balance at Jul. 31, 2020	(244,208)	$ 2	109,261	(195)	(353,276)
Beginning balance (in shares) at Jul. 31, 2020		20,128,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon initial public offering, net of underwriting discounts and issuance costs	342,685	$ 2	342,683
Issuance of common stock upon initial public offering, net of underwriting discounts and issuance costs (in shares)		17,020,000
Conversion of convertible redeemable preferred stock to common stock upon initial public offering	340,167	$ 6	340,161
Conversion of convertible redeemable preferred stock to common stock upon initial public stock offering (in shares)		63,762,000
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital upon initial public offering	512		512
Issuance of common stock upon exercise of stock options	3,992	$ 0	3,992
Issuance of common stock upon exercise of stock options (in shares)		1,301,000
Vesting of early exercised stock options	49		49
Common stock issued in connection with acquisitions	0	$ 0
Common stock issued in connection with acquisitions (in shares)		33,000
Stock-based compensation	19,077		19,077
Foreign currency translation adjustments	(51)			(51)
Net loss	(23,926)				(23,926)
Ending balance at Oct. 31, 2020	438,297	$ 10	$ 815,735	$ (246)	$ (377,202)
Ending balance (in shares) at Oct. 31, 2020		102,244,000
Beginning balance at Jul. 31, 2020	$ 340,167
Beginning balance (in shares) at Jul. 31, 2020	63,762,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Conversion of convertible redeemable preferred stock to common stock upon initial public offering	$ (340,167)
Conversion of convertible redeemable preferred stock to common stock upon initial public offering (in shares)	(63,762,000)
Ending balance (in shares) at Oct. 31, 2020	0
Ending balance at Oct. 31, 2020	$ 0

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	9 Months Ended
	Oct. 31, 2019USD ($)
Statement of Stockholders' Equity [Abstract]
Payments of issuance costs	$ 3,927

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Cash flows from operating activities
Net loss	$ (59,708)	$ (57,621)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,152	1,927
Amortization of deferred sales commissions	8,148	6,419
Stock-based compensation, net of amounts capitalized	28,666	16,561
Other	186	(11)
Changes in operating assets and liabilities, net of impact of acquisitions:
Accounts receivable	(14,717)	(5,026)
Prepaid expenses	(2,276)	513
Other assets	(619)	(57)
Deferred sales commissions	(17,718)	(10,621)
Accounts payable	(149)	56
Accrued expenses and other current liabilities	1,781	5,182
Deferred revenue	1,695	12,428
Other noncurrent liabilities	2,354	485
Net cash used in operating activities	(46,205)	(29,765)
Cash flows from investing activities
Purchases of property and equipment	(358)	(1,949)
Capitalized internal-use software costs	(1,205)	(4,292)
Cash paid for acquisitions, net of cash and restricted cash acquired	0	(8,260)
Net cash used in investing activities	(1,563)	(14,501)
Cash flows from financing activities
Proceeds from initial public offering, net of underwriting discounts	349,166	0
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	0	106,072
Proceeds from borrowings	24,250	0
Repayment of borrowings	(24,250)	0
Payments of deferred offering costs	(1,321)	(84)
Proceeds from exercise of common stock options	6,113	3,614
Cash paid for holdback consideration in connection with acquisition	(100)	0
Net cash provided by financing activities	353,858	109,602
Effect of exchange rate changes on cash and cash equivalents	(134)	(7)
Change in cash and cash equivalents and restricted cash	305,956	65,329
Beginning of period	101,813	65,671
End of period	407,769	131,000
Supplemental disclosures of cash flow information
Cash paid for income taxes	846	390
Cash paid for interest	706	10
Supplemental non-cash investing and financing information
Conversion of redeemable convertible preferred stock to common stock	340,161	0
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital	512	0
Vesting of early exercised options	148	132
Unpaid cash consideration for acquisitions	0	2,816
Stock-based compensation capitalized as internal-use software costs	321	404
Issuance of redeemable convertible preferred stock warrants	0	71
Deferred offering costs accrued but not yet paid	3,140	250
Property and equipment accrued but not yet paid	130	5
Reconciliation of cash, cash equivalents, and restricted cash to consolidated balance sheets
Total cash, cash equivalents, and restricted cash	407,769	131,000
Common Stock
Supplemental non-cash investing and financing information
Equity issued	$ 0	$ 43,873

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Oct. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Organization and Nature of Operations Sumo Logic, Inc. (the “Company”) was incorporated in Delaware in March 2010. The Company provides, on a cloud-native software-as-a-service (“SaaS”) delivery model, a software platform that enables organizations of all sizes to address the challenges and opportunities presented by digital transformation, modern applications, and cloud computing. The platform enables organizations to automate the collection, ingestion, and analysis of application, infrastructure, security, and IoT data to derive actionable insights. Basis of Presentation and Principles of Consolidation The Company’s condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission, (“SEC”), regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted, and accordingly the balance sheet as of January 31, 2020, and related disclosures, have been derived from the audited consolidated financial statements at that date but do not include all of the information required by GAAP for complete consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of only normal recurring adjustments) that are necessary for the fair statement of the Company’s condensed consolidated financial information. The results of operations for the three and nine months ended October 31, 2020 are not necessarily indicative of the results to be expected for the year ending January 31, 2021 or for any other interim period or for any other future year. The accompanying interim unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended January 31, 2020 included in the Company’s prospectus dated September 17, 2020 filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (“Prospectus”). The Company’s condensed consolidated financial statements and accompanying notes include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Fiscal Year The Company’s fiscal year ends on January 31. Unless otherwise stated, references to year in these condensed consolidated financial statements relate to the above described fiscal year rather than calendar year. Initial Public Offering On September 21, 2020, the Company completed its initial public offering (“IPO”), in which it sold 14,800,000 shares of common stock at a public offering price $22.00 per share. On October 9, 2020, the Company sold an additional 2,220,000 shares of common stock at a public offering price of $22.00 per share pursuant to the exercise of the underwriters’ option to purchase additional shares. The Company received net proceeds of $342.7 million, after deducting underwriters’ discounts and commissions and offering costs of $31.8 million. Immediately prior to the IPO, all shares of outstanding redeemable convertible preferred stock were converted into 63,761,950 shares of common stock on a one-to-one basis. Redeemable convertible preferred stock warrants also converted into 32,276 warrants to purchase common stock on a one-to-one basis.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Significant Accounting Policies Other than those described below, there have been no changes to the Company’s significant accounting policies described in the Prospectus that have had a material impact on its condensed consolidated financial statements and related notes. Use of Estimates and Judgments The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the financial statements, and the reported amounts of income and expenses during the reporting period. These estimates are based on information available as of the date of the financial statements and may involve subjective or significant judgment by the Company; therefore, actual results could differ from the Company’s estimates. The Company’s accounting policies that involve judgment include revenue recognition, period of benefit for deferred sales commissions, assumptions used for estimating the fair value of common stock to calculate stock-based compensation (prior to the closing of the IPO), capitalization of internal-use software costs, valuation of goodwill and intangible assets, certain accrued liabilities, and valuation allowances associated with income taxes. COVID-19 While the duration and extent of the COVID-19 pandemic depends on future developments that cannot be accurately predicted at this time, such as the extent and effectiveness of containment actions, it has already had an adverse effect on the global economy and the lasting effects of the pandemic continue to be unknown. The Company may experience customer losses, including due to bankruptcy or customers ceasing operations, which may result in delays in collections or an inability to collect accounts receivable from these customers. The extent to which COVID-19 may continue to impact the Company’s financial condition, results of operations, or liquidity continues to remain uncertain, and as of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or an adjustment to the carrying value of the Company’s assets or liabilities. These estimates may change, as new events occur and additional information is obtained, which will be recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates, and any such differences may be material to the Company’s financial statements. In May 2020, as part of the Company’s efforts to respond to the COVID-19 pandemic and ensure longer-term financial stability, the Company initiated cost reduction measures, including a headcount reduction. The headcount reduction resulted in $1.2 million of severance and benefits expense and $0.1 million in stock-based compensation expense for the nine months ended October 31, 2020. Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards granted to employees, directors, and non-employees based on the estimated fair values on the date of the grant. The fair value of options granted is estimated on the grant date using the Black-Scholes option pricing model. The fair value of Restricted Stock Units (“RSUs”) is estimated on the date of grant based on the fair value of the Company’s underlying common stock. The Company recognizes stock-based compensation expense for stock options on a straight-line basis. Prior to September 21, 2020, the Company recognized stock-based compensation expense for RSUs on an accelerated attribution method as the RSUs were subject to service-based and performance-based vesting conditions, which included a liquidity event condition, and in certain cases, the achievement of certain other performance metrics. None of the RSUs would vest unless the liquidity event condition was satisfied. Upon the completion of the IPO, the liquidity event condition was considered probable and the Company recognized cumulative stock-based compensation expense using the accelerated attribution method related to RSUs that had vested as of the IPO. The remaining unrecognized stock-based compensation expense related to the RSUs will be recognized over the remaining requisite service period. All RSUs granted after September 21, 2020 will not be subject to a liquidity event condition. Related Party Transactions Certain members of the Company’s board of directors serve as directors of, or are executive officers of, and in some cases are investors in, companies that are customers or vendors of the Company. Related party transactions were not material as of October 31, 2020 or January 31, 2020, or for three and nine months ended October 31, 2020 or 2019. Recently Adopted Accounting Pronouncements The Company assesses the adoption impacts of recently issued accounting pronouncements by the Financial Accounting Standards Board (“FASB”) on its condensed consolidated financial statements. The sections below describe impacts from newly adopted pronouncements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350)—Simplifying the Test for Goodwill Impairment, which simplifies the required methodology to calculate an impairment charge for goodwill. The Company adopted this guidance as of February 1, 2020, and the adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting . The amendments in the updated guidance expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted this guidance as of February 1, 2020, and the adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) , which modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures for certain investments. The Company adopted this guidance as of February 1, 2020, and the adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The Company adopted this guidance, on a prospective basis, as of February 1, 2020, and the adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) . The amendments in the updated guidance simplify the accounting for income taxes by removing certain exceptions and improving consistent application of other areas of the topic by clarifying the guidance. The Company adopted this guidance, on a prospective basis, as of February 1, 2020, and the adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. Recently Issued Accounting Pronouncements Under the JOBS Act, the Company meets the definition of an emerging growth company and can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the Company is no longer an emerging growth company or until the Company affirmatively and irrevocably opts out of the extended transition period. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . This guidance is intended to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about lease arrangements. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The ASU seeks to clarify how to apply certain aspects of the new leasing standard. In October 2018, the FASB also issued ASU No. 2018-11, Leases (Topic 842). The ASU provides (1) an optional transition method that entities can use when adopting the standard and (2) a practical expedient that permits lessors to not separate non-lease components from the associated lease component if certain conditions are met. In March 2019, the FASB also issued ASU No. 2019-01, which impacts transition disclosures related to the new guidance. In June 2020, the FASB issued ASU No. 2020-05, Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities, which amended the effective date of the new guidance. The deferral applies only if those entities have not yet issued their financial statements as of June 3, 2020. The new guidance will be effective for the Company for the fiscal year ending January 31, 2023 and interim periods within the fiscal year ending January 31, 2024. The Company is currently reviewing this guidance to assess the potential impact on its condensed consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326)

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Oct. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company measures its financial assets and liabilities at fair value each reporting period using a fair value hierarchy that prioritizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value, as follows: Level 1 Observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company uses the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The carrying amounts of the Company’s financial instruments, which include cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short maturity of those instruments. The following tables present the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis, based on the three-tier fair value hierarchy (in thousands): As of October 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 400,212 $ — $ — $ 400,212 As of January 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 98,469 $ — $ — $ 98,469 Liabilities: Redeemable convertible preferred stock warrant liability $ — $ — $ 270 $ 270 Level 3 financial liabilities consisted of the redeemable convertible preferred stock warrant liability. In connection with an agreement with Silicon Valley Bank, discussed in Note 6, the Company issued 32,276 warrants to purchase shares of the Company’s redeemable convertible preferred stock. The Company used a Black-Scholes option valuation model to value its redeemable convertible preferred stock warrant liability at inception and on subsequent valuation dates. Changes in the fair values of the redeemable convertible preferred stock warrant liability were recorded as interest and other (expense) income, net in the Company’s condensed consolidated statements of operations. All 32,276 warrants to purchase shares of redeemable convertible preferred stock

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net, consisted of the following (in thousands): October 31, January 31, Computer and hardware equipment $ 2,147 $ 1,954 Furniture and fixtures 1,213 1,129 Leasehold improvements 2,292 2,120 Capitalized internal-use software 3,386 9,823 Gross property and equipment 9,038 15,026 Accumulated depreciation and amortization (5,086) (12,033) Property and equipment, net $ 3,952 $ 2,993 Depreciation and amortization expense of property and equipment was $0.4 million and $0.3 million for the three months ended October 31, 2020 and 2019, respectively, and $1.0 million and $1.3 million for the nine months ended October 31, 2020 and 2019, respectively. The following table presents the Company’s long-lived assets by geographic region for the periods indicated (in thousands): October 31, January 31, United States $ 3,138 $ 1,970 International 814 1,023 Total long-lived assets $ 3,952 $ 2,993 The Company capitalized $0.4 million and $1.8 million of internal-use software costs for the three months ended October 31, 2020 and 2019, respectively, and $1.5 million and $4.7 million of internal-use software costs during the nine months ended October 31, 2020 and 2019, respectively. Amortization of internal-use software costs was $0.2 million and $0.2 million during the three months ended October 31, 2020 and 2019, respectively, and $0.5 million and $0.8 million during the nine months ended October 31, 2020 and 2019, respectively. There were no impairments of capitalized internal-use software costs during the nine months ended October 31, 2020 or 2019.

Acquisitions, Intangible Assets

Acquisitions, Intangible Assets, and Goodwill	9 Months Ended
	Oct. 31, 2020
Business Combinations [Abstract]
Acquisitions, Intangible Assets, and Goodwill	Acquisitions, Intangible Assets, and Goodwill Jask Labs Inc. On October 20, 2019, the Company executed a merger agreement to acquire the assets and liabilities of Jask Labs. The acquisition closed on October 25, 2019. Jask Labs is a software company with a platform that offers a cloud-native autonomous security operations center solution. The Company acquired Jask Labs primarily for its team and their platform, which includes their security analytics solution to deliver an integrated, cloud-native intelligence solution. The aggregate purchase consideration was $55.1 million, of which $11.2 million was paid in cash, $43.3 million was comprised of 3,573,659 shares of common stock, and $0.6 million was comprised of assumed options to purchase 265,075 shares of common stock. The value of consideration assigned to the common stock paid was based on the fair value of the Company’s common stock on the date of acquisition. Of the consideration transferred, $0.9 million in cash and 543,095 shares of common stock for $6.6 million was placed in an indemnity escrow fund to be held for 15 months after the acquisition date for general representations and warranties. At closing, certain Jask Labs stockholders had not completed administrative forms that were required for the Company’s common stock to be legally issued. Thus, the shares were to be issued once the administrative forms were completed. The Company has included the total fair value of the consideration for shares legally issued and legally issuable within additional-paid-in capital and common stock. As of October 31, 2020, all administrative forms were completed and all shares were legally issued and outstanding. The acquisition was accounted for as a business combination, and the total purchase price was allocated to the net tangible and intangible assets and liabilities acquired based on their respective fair values on the acquisition date and the excess was recorded as goodwill. Certain stock options held by Jask Labs employees were assumed by the Company with a total fair value of $1.7 million, of which $0.6 million was attributed to pre-combination services and was included in consideration transferred and $1.1 million was allocated to post-combination services and will be recognized as stock-based compensation over the remaining service period. See Note 9 for more details on the Jask Labs options assumed. The assets acquired and liabilities assumed in connection with the acquisition were recorded at their fair value on the date of acquisition as follows (in thousands): Amount Cash $ 782 Restricted cash 300 Accounts receivable 503 Prepaid expenses and other assets 659 Fixed assets 367 Intangible assets 17,500 Goodwill 41,368 Accounts payable (1,760) Deferred revenue, current (2,358) Accrued and other current liabilities (1,609) Deferred revenue, noncurrent (354) Other noncurrent liabilities (291) Total acquisition consideration $ 55,107 Subsequent to the acquisition, the Company recorded a $0.3 million tax benefit related to on the release of the valuation allowance on its net deferred tax assets. Intangible assets acquired are comprised of developed technology with an estimated useful life of 3 years. The fair value assigned to the developed technology was determined using the reproduction cost approach, which estimates the cost to reproduce the asset. Goodwill represents the future economic benefits arising from other assets that could not be individually identified and separately recognized, such as the acquired assembled workforce of Jask Labs. In addition, goodwill represents the future benefits as a result of the acquisition that will enhance the Company’s product available to both new and existing customers and increase the Company’s competitive position. The goodwill is not deductible for tax purposes. In connection with the acquisition, the Company granted 130,180 shares of restricted common stock, with a fair value of $12.11683 per share at the time of grant, that vest over a period of two years. The Company recorded stock-based compensation expense related to the vesting of the restricted common stock of $0.2 million during the three months ended October 31, 2020 and $0.6 million during the nine months ended October 31, 2020. Stock-based compensation expense related to the vesting of the restricted common stock was immaterial for the nine months ended October 31, 2019. As of October 31, 2020 and January 31, 2020, the remaining unrecognized stock-based compensation expense of $0.8 million and $1.4 million, respectively, will be recognized over the remaining vesting period. The Company incurred acquisition-related expenses of $2.6 million, which were recorded as general and administrative expenses in the condensed consolidated statement of operations during the three and nine months ended October 31, 2019. The Company paid $0.8 million in acquisition-related expenses incurred by Jask Labs related to Jask Labs’ advisors which was included as part of the purchase consideration. The results of operations of Jask Labs are included in the accompanying condensed consolidated statements of operations from the date of acquisition. Jask Labs’ results of operations since the date of acquisition were not material to the Company’s condensed consolidated results for the year ended January 31, 2020. Pro Forma Financial Information The following pro forma information gives effect to the acquisition of Jask Labs as if it had been completed on February 1, 2017 (the beginning of the comparable prior annual reporting period presented in the Prospectus), including pro forma adjustments primarily related to amortization of acquired intangible assets, reduction in revenue related to the fair value of deferred revenue, stock-based compensation, tax benefit from release of the valuation allowance, and the inclusion of acquisition-related expenses reflected in the revenue and net loss figures below at the earliest period presented. The pro forma results have been prepared based on estimates and assumptions, which the Company believes are reasonable; however, they are not necessarily indicative of the consolidated results of operations had the acquisition occurred on February 1, 2017, or of future results of operations (in thousands): Three Months Ended Nine Months Ended Revenue $ 41,503 $ 113,124 Net loss $ (34,258) $ (81,025) Pro forma revenue and net loss reflect nonrecurring adjustments for acquisition-related expenses of $3.4 million, a tax benefit of $0.3 million for the release of the valuation allowance, and accelerated stock-based compensation of $0.1 million that resulted from the acquisition. Other Acquisitions During the nine months ended October 31, 2019, the Company completed an asset acquisition for total consideration of $1.0 million which was attributed to intangible assets. The intangible assets acquired in the asset acquisition were comprised of developed technology with an estimated weighted average useful life of 1.5 years. This acquisition generally enhances the breadth and depth of certain of the Company’s product offerings. Acquired Intangible Assets Intangible assets as of October 31, 2020 and January 31, 2020 consisted of developed technology with acquisition-date fair values of $20.1 million and $20.1 million, respectively. As of October 31, 2020 and January 31, 2020, the accumulated amortization of the developed technology was $7.8 million and $2.7 million, respectively. As of October 31, 2020 and January 31, 2020, the weighted-average remaining useful life of the developed technology was 2.0 years and 2.7 years, respectively. The Company recorded amortization expense of $1.7 million and $0.3 million during the three months ended October 31, 2020 and 2019, respectively, and $5.1 million and $0.6 million during the nine months ended October 31, 2020 and 2019, respectively. There was no impairment of intangible assets recorded for the nine months ended October 31, 2020 or 2019. As of October 31, 2020, future amortization expense related to acquired developed technology was as follows (in thousands): Amortization Expense Remainder of fiscal 2021 $ 1,648 2022 6,148 2023 4,502 Total. $ 12,298 As of January 31, 2020, future amortization expense related to acquired developed technology was as follows (in thousands): Amortization Expense 2021 $ 6,765 2022 6,148 2023 4,502 Total $ 17,415 Goodwill

Debt

Debt	9 Months Ended
	Oct. 31, 2020
Debt Disclosure [Abstract]
Debt	Debt On January 31, 2016, the Company entered into a Loan and Security Agreement (the “Agreement”) with Silicon Valley Bank. The Agreement provides for a revolving line of credit facility, which was amended in July 2019 to extend it to July 31, 2021. Under the Agreement, the Company can borrow up to $25 million. Interest on any drawdown under the revolving line of credit accrues either at the prime rate plus a spread rate of ranging from 0.25% to 0.75% as determined by the Company’s adjusted quick ratio. The Agreement is secured by substantially all of the Company’s assets. The Agreement includes restrictive covenants, in each case subject to certain exceptions, that limit the Company’s ability to: sell or otherwise dispose of the Company’s business or property; change its business, liquidate or dissolve or undergo a change in control; enter into mergers, consolidations, and acquisitions; incur indebtedness; create liens; pay dividends or make distributions; make investments; enter into material transactions with affiliates; pay any subordinated debt or amend certain terms thereof; or become an investment company. The Agreement also contains customary events of default, upon which Silicon Valley Bank may declare all or a portion of the Company’s outstanding obligations payable to be immediately due and payable. In June 2020, the Company amended the Agreement with Silicon Valley Bank to extend its maturity to June 2022. Under the amended Agreement, the Company can borrow up to $50 million. Interest on any drawdown accrues at the greater of the prime rate plus a spread of 0.75% or 5.25%. Pursuant to the amended Agreement, the Company is required to maintain a minimum adjusted quick ratio of 1.25 to 1.00. If the Company’s adjusted quick ratio is greater than or equal to 1.75 to 1.00, interest on any drawdown will accrue at the greater of the prime rate plus a spread of 0.25% or 4.75%. The revolving line of credit must be repaid by June 26, 2022. During the three months ended October 31, 2020, the Company repaid the outstanding balance under this facility. The Company did not have any balance outstanding under this facility as of January 31, 2020. The Company was in compliance with the financial covenants associated with the amended Agreement as of October 31, 2020.

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Oct. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases The Company leases office space globally under non-cancelable operating lease agreements that expire at various dates through fiscal 2025. As of October 31, 2020, future annual minimum lease payments under non-cancelable operating leases were as follows (in thousands): Minimum Remainder of 2021 $ 1,199 2022 4,787 2023 4,649 2024 1,887 2025 404 Total $ 12,926 Rent expense was $1.0 million and $0.9 million for the three months ended October 31, 2020 and 2019, respectively, and $3.0 million and $2.3 million for the nine months ended October 31, 2020 and 2019, respectively. Non-Cancellable Purchase Commitments During the nine months ended October 31, 2020, there were no material changes, outside the ordinary course of business, to the Company’s contractual obligations and commitments, except as follows. In July 2020, the Company entered into an amended hosting agreement effective August 2020. Under the amended agreement, the Company has committed to spend $220.0 million between August 2020 and January 2024 for its hosting agreement ($90.0 million between August 2020 and January 2022, $60 million between February 2022 and January 2023, and $70.0 million between February 2023 and January 2024). Litigation and Other Matters From time to time, the Company may be a party to various legal matters, threatened claims, or proceedings in the normal course of business. Legal fees and other costs associated with such actions are expensed as incurred. The Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and contingencies. Legal accruals are recorded when and if it is determined that a loss related to a certain matter is both probable and reasonably estimable. Attorneys representing a purported class of current and former employees in various sales roles alleged potential claims of employee misclassification and related federal and state law claims, which the Company disputed. In response, the Company mediated the dispute, and in August 2020, the Company entered into a settlement agreement with the purported class counsel to resolve the dispute, which is being handled in arbitration and will result in the Company paying $4.5 million to resolve the class-wide claims, subject to final approval by the arbitrator. As of October 31, 2020, the Company had recorded $4.5 million related to these claims within accrued expenses and other current liabilities on the condensed consolidated balance sheet.

Revenue

Revenue	9 Months Ended
	Oct. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Disaggregation of Revenue The following table presents the Company’s revenue by geographic region, based on the billing address of the customer, for the periods indicated (in thousands): Three Months Ended October 31, Nine Months Ended October 31, 2020 2019 2020 2019 United States $ 44,636 $ 34,355 $ 125,648 $ 93,269 International 7,232 6,158 22,837 17,476 Total revenue $ 51,868 $ 40,513 $ 148,485 $ 110,745 No individual foreign country contributed 10% or more of revenue for the three and nine months ended October 31, 2020 and 2019. No customer individually accounted for 10% or more of the Company’s revenue for the three and nine months ended October 31, 2020 or 2019. Deferred Revenue, and Remaining Performance Obligations The Company recognized revenue of $38.1 million and $29.7 million during the three months ended October 31, 2020 and 2019, respectively, and $77.6 million and $55.9 million during the nine months ended October 31, 2020 and 2019, respectively, that was included in the deferred revenue balance at the beginning of the respective periods. As of October 31, 2020, future estimated revenue related to performance obligations from non-cancelable contracts that were unsatisfied or partially unsatisfied were $234.4 million. Of this amount, the Company expects to recognize revenue of approximately $139.9 million over the next twelve months, with the remaining balance recognized thereafter. Accounts Receivable and Related Allowance Accounts receivable consist of amounts billed and currently due from customers. The Company’s accounts receivable are subject to collection risk. Gross accounts receivable is adjusted for estimated losses resulting from the inability of the Company’s customers to fulfill their payment obligations. The Company periodically reviews factors such as past collection experience, specific allowances for known troubled accounts, and other currently available evidence to determine the best estimate of probable losses inherent in the receivables. As of October 31, 2020, there wa s less tha n $0.1 million rec orded as an allowance for doubtful accounts for the Company’s accounts receivables, and there was no allowance for doubtful accounts as of January 31, 2020. As of October 31, 2020, two customers accounted for 19% and 11% of total accounts receivable, respectively. As of January 31, 2020, no individual customer accounted for 10% or more of total accounts receivable. Deferred Sales Commissions The Company capitalized sales commission of $10.8 million and $4.0 million during the three months ended October 31, 2020 and 2019, respectively, and $17.7 million and $10.6 million during the nine months ended October 31, 2020 and 2019, respectively. Amortized costs were $2.9 million and $2.2 million for the three months ended October 31, 2020 and 2019, respectively, and $8.1 million and $6.4 million for the nine months ended October 31, 2020 and 2019, respectively. There was no impairment loss in relation to deferred sales commissions for the nine months ended October 31, 2020 or 2019.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) and Equity Incentive Plans	9 Months Ended
	Oct. 31, 2020
Equity [Abstract]
Stockholders' Equity (Deficit) and Equity Incentive Plans	Stockholders’ Equity (Deficit) and Equity Incentive Plans Redeemable Convertible Preferred Stock Upon the closing of the Company’s IPO, all 63,761,950 shares of redeemable convertible preferred stock were automatically converted into shares of common stock on a one-to-one basis, and the carrying value of $340.2 million was reclassified into common stock and additional paid-in-capital. As of October 31, 2020, there were no shares of redeemable convertible preferred stock issued and outstanding. Common Stock The Company’s Amended and Restated Certificate of Incorporation authorized the Company to issue 1,000.0 million and 122.0 million shares of common stock at a par value of $0.0001 as of October 31, 2020 and January 31, 2020, respectively. As of October 31, 2020 and January 31, 2020, approximately 102.0 million and 19.0 million shares of common stock were issued and outstanding, respectively. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding. As of October 31, 2020 and January 31, 2020, no dividends had been declared. Stock Plans The Company has two equity incentive plans: the 2010 Stock Plan (the “2010 Plan”) and the 2020 Equity Incentive Plan (the “2020 Plan”). In connection with the Company’s IPO in September 2020, the 2010 Plan was terminated and replaced by the 2020 Plan and all shares that remained available for issuance under the 2010 Plan at that time were reserved for issuance under the 2020 Plan. The number of shares of common stock available for issuance under the 2020 Plan will be increased by any shares of common stock subject to awards outstanding under the 2010 Plan that expire or otherwise terminate without having been exercised or issued in full, are tendered to or withheld by the Company for payment of an exercise price or for satisfying tax withholding obligations, or are forfeited to or repurchased by the Company due to failure to vest . The Company has issued stock options and restricted stock units (“RSUs”) to employees, directors, consultants, and advisors pursuant to the 2010 Plan. Through October 31, 2020, the Company has granted no equity awards pursuant to the 2020 Plan. Employee stock options are granted with an exercise price no less than the fair value of the underlying common stock on the grant date, in general vest based on continuous service over four years, and expire 10 years from the date of grant. The value of RSUs is measured based on the grant date fair value of the awards and in general vest based on satisfying both a service-based condition based on continuous service over four years and a liquidity event condition. As of October 31, 2020, there were 13.3 million shares available for grant under the 2020 Plan. The 2020 Plan provides that the number of shares reserved will automatically increase on the first day of each fiscal year, beginning on February 1, 2021, by an amount equal to the least of (i) 12,500,000 shares, (ii) 5% of the outstanding shares of our common stock on the last day of the immediately preceding fiscal year, or (iii) such other amount as the administrator of the 2020 Plan may determine. Stock Options The following table is a summary of option activity during the nine months ended October 31, 2020: Number of Weighted Weighted Aggregate (in thousands) (years) (in thousands) Balance at January 31, 2020 27,841 $ 3.72 7.7 $ 233,918 Options granted 1,635 $ 12.12 Options exercised (2,170) $ 2.61 Options cancelled (2,072) $ 6.08 Balance at October 31, 2020 25,234 $ 4.16 7.0 $ 331,066 Options exercisable at January 31, 2020 14,141 $ 2.01 6.5 $ 142,932 Options exercisable at October 31, 2020 15,710 $ 2.61 6.1 $ 230,411 Stock options granted during the three months ended October 31, 2020 and 2019 had a weighted-average grant-date fair value $11.13 and $6.68 per share, respectively. The aggregate intrinsic value of options exercised during the three months ended October 31, 2020 and 2019 was $17.0 million and $6.7 million, respectively. Stock options granted during the nine months ended October 31, 2020 and 2019 had a weighted-average grant date fair value of $6.21 and $5.46 per share, respectively. The aggregate intrinsic value of options exercised during the nine months ended October 31, 2020 and 2019 was $25.9 million and $9.9 million, respectively. No income tax benefits have been recognized for stock-based compensation arrangements. As of October 31, 2020 and January 31, 2020, there was $40.4 million and $52.0 million, respectively, of total unrecognized compensation expense related to unvested employee and non-employee stock options that is expected to be recognized over a weighted-average period of 2.6 and 3.1 years, respectively. Early Exercise of Employee Options As of October 31, 2020 and January 31, 2020, the Company had a liability $0.3 million and $0.4 million, respectively, for 91,375 and 139,750 shares of common stock that were unvested and early exercised by employees as of October 31, 2020 and January 31, 2020, respectively. Restricted Stock Units The following table is a summary of RSU activity for the nine months ended October 31, 2020: Number of Shares Weighted (in thousands) RSUs outstanding at February 1, 2020 — Granted 3,274 $ 13.03 Forfeited (83) $ 12.12 RSUs outstanding at October 31, 2020 3,191 $ 13.06 RSUs expected to vest at October 31, 2020 3,191 $ 13.06 As of October 31, 2020, there was $27.7 million of total unrecognized compensation expense related to unvested employee and director RSUs, of which $1.0 million is for the RSUs subject to certain other performance metrics. Total unrecognized compensation expense related to unvested RSUs is expected to be recognized over a weighted-average period of 1.8 years. Jask Labs Plans In connection with the acquisition of Jask Labs, the Company assumed 265,075 options to purchase shares of common stock, granted under the Jask Labs 2015 Stock Option and Grant Plan and the Jask Labs 2018 Equity Incentive Plan (together, the “Jask Plans”), at a weighted-average exercise price of $9.86 per share and weighted-average fair value of $6.39 per share, of which 142,096 and 233,852 remained outstanding as of October 31, 2020 and January 31, 2020, respectively. As of October 31, 2020 and January 31, 2020, 95,079 and 124,184 options were vested and exercisable with a weighted-average exercise price of $9.79 and $9.21, and the total unrecognized compensation expense related to these awards was $0.3 million and $0.6 million, respectively. During the nine months ended October 31, 2020, 52,073 options were exercised. Stock-Based Compensation Expense The following table presents total stock-based compensation expense included in the condensed consolidated statements of operations (in thousands): Three Months Ended October 31, Nine Months Ended October 31, 2020 2019 2020 2019 Cost of revenue $ 213 $ 50 $ 314 $ 96 Research and development (a) 5,728 2,474 9,606 3,953 Sales and marketing 4,747 1,960 7,863 3,866 General and administrative (b) 8,255 5,244 10,883 8,646 Total $ 18,943 $ 9,728 $ 28,666 $ 16,561 ________________ (a) The Company capitalized stock-based compensation related to internal-use software development costs of $0.1 million and $0.2 million, during the three months ended October 31, 2020 and 2019, respectively, and $0.3 million, and $0.4 million, during the nine months ended October 31, 2020 and 2019, respectively. The research and development stock-based compensation amounts are presented net of the capitalized costs. (b) During the three and nine months ended October 31, 2019, the Company’s board of directors approved modifications to immediately vest 172,708 options that had been granted previously, resulting in additional stock-based compensation expense of $1.6 million, which was recorded to general and administrative expenses during the three and nine months ended October 31, 2019. During the year ended January 31, 2020, the Company granted 280,316 options to certain executives that were subject to both service-based vesting conditions and performance-based vesting conditions; as the performance-based vesting conditions were not met, no stock-based compensation was recognized on these options for the year ended January 31, 2020. During the nine months ended October 31, 2020, these options were cancelled. The RSUs granted under the 2010 Plan were subject to service-based and performance-based vesting conditions, which included a liquidity event condition. In certain cases the RSUs are also subject to certain other performance metrics. The liquidity event performance-based vesting condition was deemed probable of occurring up on the completion of the IPO. On that date we recorded cumulative stock-based compensation expense of $10.9 million using the accelerated attribution method. The remaining unrecognized stock-based compensation expense will be recorded over the RSUs remaining requisite service periods. Included within these amounts was $1.4 million for the RSUs subject to both the occurrence of a liquidity event and certain other performance metrics. Employee Stock Purchase Plan In September 2020, the board of directors adopted and the stockholders of the Company approved the 2020 Employee Stock Purchase Plan, (“ESPP”), which became effective on September 17, 2020. The ESPP initially reserved and authorized the issuance of up to a total of 2,000,000 shares of common stock to participating employees. The number of shares reserved under the ESPP will automatically increase on the first day of each fiscal year, starting on February 1, 2021, in an amount equal to the least of (i) 2,500,000 shares, (ii) 1% of the outstanding shares of our common stock on the last day of the immediately preceding fiscal year, or (iii) such other amount as the administrator of the ESPP may determine. The ESPP generally provides for 24-month offering periods beginning June 15 and December 15 of each year, with each offering period consisting of four six-month purchase periods, except for the initial offering period which began on September 17, 2020, and will end on December 15, 2022 and the second offering period will begin on June 15, 2021. On each purchase date, eligible employees will purchase the shares at a price per share equal to 85% of the lesser of (1) the fair market value of the Company’s common stock as of the beginning of the offering period or (2) the fair market value of the Company’s common stock on the purchase date, as defined in the ESPP. The Company recognized stock-based compensation expense related to ESPP of $0.3 million during the three and nine months ended October 31, 2020. As of October 31, 2020, $0.6 million amount has been withheld on behalf of employees for a future purchase under the ESPP due to the timing of payroll deductions. As of October 31, 2020, there was $8.3 million of unrecognized stock-based compensation expense related to the ESPP that is expected to be recognized over an average vesting period of 1.4 years. There were no purchases for the three or nine months ended October 31, 2019 related to the ESPP. Common Stock Transfers During the nine months ended October 31, 2020 and 2019, certain of the Company’s existing investors acquired outstanding common stock from former employees of the Company, for a purchase price greater than the fair value of the common stock at the time of the transaction. In connection with these stock transfers, the Company waived its right of first refusal and other transfer restrictions applicable to such shares. As a result, the Company recorded stock-based compensation of $0.3 million and $1.4 million for the nine months ended October 31, 2020 and 2019, respectively, in general and administrative expenses in the condensed consolidated statements of operations. The amount recorded as stock-based compensation represents the difference between the price paid and the estimated fair value at the date of the transaction. During the three and nine months ended October 31, 2019, the Company facilitated a tender offer whereby certain existing investors commenced a tender offer to purchase shares of the Company’s common stock from certain employees and former employees of the Company, for $12.11683 per share, in cash. An aggregate of 1,686,446 shares of the Company’s common stock were tendered pursuant to the tender offer. During the three and nine months ended October 31, 2019, the Company recorded a total of $4.8 million in stock-based compensation related to the tender offer, comprised of $2.6 million in general and administrative expenses, $1.5 million in research and development expenses, $0.7 million in sales and marketing expenses, and less than $0.1 million in cost of revenue in the condensed consolidated statements of operations. The amounts recorded as stock-based compensation represent the difference between the amounts paid over the estimated fair value at the date of the transaction.

Income Taxes

Income Taxes	9 Months Ended
	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Accounting for income taxes for interim periods generally requires the provision for income taxes to be determined by applying an estimate of the annual effective tax rate for the full fiscal year to income or loss before income taxes, adjusted for discrete items, if any, for the reporting period. The Company updates its estimate of the annual effective tax rate each quarter and records a cumulative adjustment in such period. The Company recorded income tax expense of $0.4 million and less than $0.1 million for the three months ended October 31, 2020 and 2019, respectively, and $0.8 million and $0.4 million for the nine months ended October 31, 2020 and 2019, respectively. Income tax expense consists primarily of income taxes in foreign jurisdictions in which the Company conducts business. Due to the Company’s history of losses in the United States, a full valuation allowance on substantially all of the Company’s deferred tax assets, including net operating loss carryforwards, research and development tax credits, capitalized research and development, and other book versus tax differences was maintained.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Oct. 31, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss per Share Basic net loss per share attributable to the Company’s common stockholders is computed by dividing the net loss attributable to the Company’s common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all years presented because the effects of potentially dilutive items were anti-dilutive given the Company’s net loss position in each period presented. The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share data): Three Months Ended October 31, Nine Months Ended October 31, 2020 2019 2020 2019 Net loss $ (23,926) $ (28,619) $ (59,708) $ (57,621) Weighted-average shares outstanding, basic and diluted 55,816 14,650 31,044 13,953 Net loss per share, basic and diluted $ (0.43) $ (1.95) $ (1.92) $ (4.13) The following potential common shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (in thousands): Three Months Ended October 31, Nine Months Ended October 31, 2020 2019 2020 2019 Stock options 25,234 28,556 25,234 28,556 RSUs 3,191 — 3,191 — ESPP 44 — 44 — Redeemable convertible preferred stock warrants 32 32 32 32 Shares subject to repurchase 166 436 166 436 Assumed options for Jask Labs acquisition 142 265 142 265 Issuable shares for Jask Labs acquisition 543 1,325 543 1,325 Redeemable convertible preferred stock — 63,762 — 63,762 Total anti-dilutive securities 29,352 94,376 29,352 94,376

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	The Company’s condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission, (“SEC”), regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted, and accordingly the balance sheet as of January 31, 2020, and related disclosures, have been derived from the audited consolidated financial statements at that date but do not include all of the information required by GAAP for complete consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of only normal recurring adjustments) that are necessary for the fair statement of the Company’s condensed consolidated financial information. The results of operations for the three and nine months ended October 31, 2020 are not necessarily indicative of the results to be expected for the year ending January 31, 2021 or for any other interim period or for any other future year. The accompanying interim unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended January 31, 2020 included in the Company’s prospectus dated September 17, 2020 filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (“Prospectus”).
Principles of Consolidation	The Company’s condensed consolidated financial statements and accompanying notes include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Fiscal Year	The Company’s fiscal year ends on January 31. Unless otherwise stated, references to year in these condensed consolidated financial statements relate to the above described fiscal year rather than calendar year.
Use of Estimates and Judgments	The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the financial statements, and the reported amounts of income and expenses during the reporting period. These estimates are based on information available as of the date of the financial statements and may involve subjective or significant judgment by the Company; therefore, actual results could differ from the Company’s estimates. The Company’s accounting policies that involve judgment include revenue recognition, period of benefit for deferred sales commissions, assumptions used for estimating the fair value of common stock to calculate stock-based compensation (prior to the closing of the IPO), capitalization of internal-use software costs, valuation of goodwill and intangible assets, certain accrued liabilities, and valuation allowances associated with income taxes.
Covid-19	While the duration and extent of the COVID-19 pandemic depends on future developments that cannot be accurately predicted at this time, such as the extent and effectiveness of containment actions, it has already had an adverse effect on the global economy and the lasting effects of the pandemic continue to be unknown. The Company may experience customer losses, including due to bankruptcy or customers ceasing operations, which may result in delays in collections or an inability to collect accounts receivable from these customers. The extent to which COVID-19 may continue to impact the Company’s financial condition, results of operations, or liquidity continues to remain uncertain, and as of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or an adjustment to the carrying value of the Company’s assets or liabilities. These estimates may change, as new events occur and additional information is obtained, which will be recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates, and any such differences may be material to the Company’s financial statements.
Stock-based Compensation	The Company measures and recognizes compensation expense for all stock-based payment awards granted to employees, directors, and non-employees based on the estimated fair values on the date of the grant. The fair value of options granted is estimated on the grant date using the Black-Scholes option pricing model. The fair value of Restricted Stock Units (“RSUs”) is estimated on the date of grant based on the fair value of the Company’s underlying common stock. The Company recognizes stock-based compensation expense for stock options on a straight-line basis. Prior to September 21, 2020, the Company recognized stock-based compensation expense for RSUs on an accelerated attribution method as the RSUs were subject to service-based and performance-based vesting conditions, which included a liquidity event condition, and in certain cases, the achievement of certain other performance metrics. None of the RSUs would vest unless the liquidity event condition was satisfied. Upon the completion of the IPO, the liquidity event condition was considered probable and the Company recognized cumulative stock-based compensation expense using the accelerated attribution method related to RSUs that had vested as of the IPO. The remaining unrecognized stock-based compensation expense related to the RSUs will be recognized over the remaining requisite service period. All RSUs granted after September 21, 2020 will not be subject to a liquidity event condition.
Related Party Transactions	Certain members of the Company’s board of directors serve as directors of, or are executive officers of, and in some cases are investors in, companies that are customers or vendors of the Company.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Company assesses the adoption impacts of recently issued accounting pronouncements by the Financial Accounting Standards Board (“FASB”) on its condensed consolidated financial statements. The sections below describe impacts from newly adopted pronouncements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350)—Simplifying the Test for Goodwill Impairment, which simplifies the required methodology to calculate an impairment charge for goodwill. The Company adopted this guidance as of February 1, 2020, and the adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting . The amendments in the updated guidance expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted this guidance as of February 1, 2020, and the adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) , which modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures for certain investments. The Company adopted this guidance as of February 1, 2020, and the adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The Company adopted this guidance, on a prospective basis, as of February 1, 2020, and the adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) . The amendments in the updated guidance simplify the accounting for income taxes by removing certain exceptions and improving consistent application of other areas of the topic by clarifying the guidance. The Company adopted this guidance, on a prospective basis, as of February 1, 2020, and the adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. Recently Issued Accounting Pronouncements Under the JOBS Act, the Company meets the definition of an emerging growth company and can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the Company is no longer an emerging growth company or until the Company affirmatively and irrevocably opts out of the extended transition period. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . This guidance is intended to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about lease arrangements. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The ASU seeks to clarify how to apply certain aspects of the new leasing standard. In October 2018, the FASB also issued ASU No. 2018-11, Leases (Topic 842). The ASU provides (1) an optional transition method that entities can use when adopting the standard and (2) a practical expedient that permits lessors to not separate non-lease components from the associated lease component if certain conditions are met. In March 2019, the FASB also issued ASU No. 2019-01, which impacts transition disclosures related to the new guidance. In June 2020, the FASB issued ASU No. 2020-05, Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities, which amended the effective date of the new guidance. The deferral applies only if those entities have not yet issued their financial statements as of June 3, 2020. The new guidance will be effective for the Company for the fiscal year ending January 31, 2023 and interim periods within the fiscal year ending January 31, 2024. The Company is currently reviewing this guidance to assess the potential impact on its condensed consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326)
Fair Value Measurements	The Company measures its financial assets and liabilities at fair value each reporting period using a fair value hierarchy that prioritizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value, as follows: Level 1 Observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company uses the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Oct. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables present the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis, based on the three-tier fair value hierarchy (in thousands): As of October 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 400,212 $ — $ — $ 400,212 As of January 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 98,469 $ — $ — $ 98,469 Liabilities: Redeemable convertible preferred stock warrant liability $ — $ — $ 270 $ 270

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment, net, consisted of the following (in thousands): October 31, January 31, Computer and hardware equipment $ 2,147 $ 1,954 Furniture and fixtures 1,213 1,129 Leasehold improvements 2,292 2,120 Capitalized internal-use software 3,386 9,823 Gross property and equipment 9,038 15,026 Accumulated depreciation and amortization (5,086) (12,033) Property and equipment, net $ 3,952 $ 2,993
Long-lived Assets by Geographic Areas	The following table presents the Company’s long-lived assets by geographic region for the periods indicated (in thousands): October 31, January 31, United States $ 3,138 $ 1,970 International 814 1,023 Total long-lived assets $ 3,952 $ 2,993

Acquisitions, Intangible Asse_2

Acquisitions, Intangible Assets, and Goodwill (Tables)	9 Months Ended
	Oct. 31, 2020
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The assets acquired and liabilities assumed in connection with the acquisition were recorded at their fair value on the date of acquisition as follows (in thousands): Amount Cash $ 782 Restricted cash 300 Accounts receivable 503 Prepaid expenses and other assets 659 Fixed assets 367 Intangible assets 17,500 Goodwill 41,368 Accounts payable (1,760) Deferred revenue, current (2,358) Accrued and other current liabilities (1,609) Deferred revenue, noncurrent (354) Other noncurrent liabilities (291) Total acquisition consideration $ 55,107
Business Acquisition, Pro Forma Information	The following pro forma information gives effect to the acquisition of Jask Labs as if it had been completed on February 1, 2017 (the beginning of the comparable prior annual reporting period presented in the Prospectus), including pro forma adjustments primarily related to amortization of acquired intangible assets, reduction in revenue related to the fair value of deferred revenue, stock-based compensation, tax benefit from release of the valuation allowance, and the inclusion of acquisition-related expenses reflected in the revenue and net loss figures below at the earliest period presented. The pro forma results have been prepared based on estimates and assumptions, which the Company believes are reasonable; however, they are not necessarily indicative of the consolidated results of operations had the acquisition occurred on February 1, 2017, or of future results of operations (in thousands): Three Months Ended Nine Months Ended Revenue $ 41,503 $ 113,124 Net loss $ (34,258) $ (81,025)
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	As of October 31, 2020, future amortization expense related to acquired developed technology was as follows (in thousands): Amortization Expense Remainder of fiscal 2021 $ 1,648 2022 6,148 2023 4,502 Total. $ 12,298 As of January 31, 2020, future amortization expense related to acquired developed technology was as follows (in thousands): Amortization Expense 2021 $ 6,765 2022 6,148 2023 4,502 Total $ 17,415

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	9 Months Ended
	Oct. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	As of October 31, 2020, future annual minimum lease payments under non-cancelable operating leases were as follows (in thousands): Minimum Remainder of 2021 $ 1,199 2022 4,787 2023 4,649 2024 1,887 2025 404 Total $ 12,926

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Oct. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents the Company’s revenue by geographic region, based on the billing address of the customer, for the periods indicated (in thousands): Three Months Ended October 31, Nine Months Ended October 31, 2020 2019 2020 2019 United States $ 44,636 $ 34,355 $ 125,648 $ 93,269 International 7,232 6,158 22,837 17,476 Total revenue $ 51,868 $ 40,513 $ 148,485 $ 110,745

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) and Equity Incentive Plans (Tables)	9 Months Ended
	Oct. 31, 2020
Equity [Abstract]
Share-based Payment Arrangement, Option, Activity	The following table is a summary of option activity during the nine months ended October 31, 2020: Number of Weighted Weighted Aggregate (in thousands) (years) (in thousands) Balance at January 31, 2020 27,841 $ 3.72 7.7 $ 233,918 Options granted 1,635 $ 12.12 Options exercised (2,170) $ 2.61 Options cancelled (2,072) $ 6.08 Balance at October 31, 2020 25,234 $ 4.16 7.0 $ 331,066 Options exercisable at January 31, 2020 14,141 $ 2.01 6.5 $ 142,932 Options exercisable at October 31, 2020 15,710 $ 2.61 6.1 $ 230,411
Share-based Payment Arrangement, Restricted Stock Unit, Activity	The following table is a summary of RSU activity for the nine months ended October 31, 2020: Number of Shares Weighted (in thousands) RSUs outstanding at February 1, 2020 — Granted 3,274 $ 13.03 Forfeited (83) $ 12.12 RSUs outstanding at October 31, 2020 3,191 $ 13.06 RSUs expected to vest at October 31, 2020 3,191 $ 13.06
Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following table presents total stock-based compensation expense included in the condensed consolidated statements of operations (in thousands): Three Months Ended October 31, Nine Months Ended October 31, 2020 2019 2020 2019 Cost of revenue $ 213 $ 50 $ 314 $ 96 Research and development (a) 5,728 2,474 9,606 3,953 Sales and marketing 4,747 1,960 7,863 3,866 General and administrative (b) 8,255 5,244 10,883 8,646 Total $ 18,943 $ 9,728 $ 28,666 $ 16,561 ________________ (a) The Company capitalized stock-based compensation related to internal-use software development costs of $0.1 million and $0.2 million, during the three months ended October 31, 2020 and 2019, respectively, and $0.3 million, and $0.4 million, during the nine months ended October 31, 2020 and 2019, respectively. The research and development stock-based compensation amounts are presented net of the capitalized costs. (b) During the three and nine months ended October 31, 2019, the Company’s board of directors approved modifications to immediately vest 172,708 options that had been granted previously, resulting in additional stock-based compensation expense of $1.6 million, which was recorded to general and administrative expenses during the three and nine months ended October 31, 2019.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Oct. 31, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share data): Three Months Ended October 31, Nine Months Ended October 31, 2020 2019 2020 2019 Net loss $ (23,926) $ (28,619) $ (59,708) $ (57,621) Weighted-average shares outstanding, basic and diluted 55,816 14,650 31,044 13,953 Net loss per share, basic and diluted $ (0.43) $ (1.95) $ (1.92) $ (4.13)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potential common shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (in thousands): Three Months Ended October 31, Nine Months Ended October 31, 2020 2019 2020 2019 Stock options 25,234 28,556 25,234 28,556 RSUs 3,191 — 3,191 — ESPP 44 — 44 — Redeemable convertible preferred stock warrants 32 32 32 32 Shares subject to repurchase 166 436 166 436 Assumed options for Jask Labs acquisition 142 265 142 265 Issuable shares for Jask Labs acquisition 543 1,325 543 1,325 Redeemable convertible preferred stock — 63,762 — 63,762 Total anti-dilutive securities 29,352 94,376 29,352 94,376

Description of Business and B_2

Description of Business and Basis of Presentation (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 09, 2020	Sep. 21, 2020	Oct. 09, 2020	Oct. 31, 2020	Oct. 31, 2020	Oct. 31, 2019	Jan. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Underwriters' discounts and commissions and offering costs					$ 1,321	$ 84
Convertible preferred stock converted into common stock per share (in shares)		1
Deferred offering costs		$ 6,500					$ 3,300
Common Stock
Subsidiary, Sale of Stock [Line Items]
Conversion of convertible redeemable preferred stock to common stock upon initial public stock offering (in shares)		63,761,950		63,762,000	63,762,000
Redeemable convertible preferred stock warrants
Subsidiary, Sale of Stock [Line Items]
Number of redeemable convertible preferred stock warrants converted (in shares)		32,276
Number of redeemable convertible preferred stock warrants converted per share (in shares)		1
IPO
Subsidiary, Sale of Stock [Line Items]
Number of shares sold (in shares)		14,800,000
Price of shares sold (in USD per share)	$ 22	$ 22	$ 22
Net proceeds from shares sold			$ 342,700
Underwriters' discounts and commissions and offering costs			$ 31,800
Underwriter's Option
Subsidiary, Sale of Stock [Line Items]
Number of shares sold (in shares)	2,220,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Restructuring Cost and Reserve [Line Items]
Stock-based compensation expense	$ 18,943	$ 9,728	$ 28,666	$ 16,561
COVID-19 Pandemic
Restructuring Cost and Reserve [Line Items]
Severance			1,200
Stock-based compensation expense			$ 100

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Oct. 31, 2020	Jan. 31, 2020
Liabilities:
Redeemable convertible preferred stock warrant liability		$ 270
Money market funds
Assets:
Money market funds	$ 400,212	98,469
Level 1
Liabilities:
Redeemable convertible preferred stock warrant liability		0
Level 1 | Money market funds
Assets:
Money market funds	400,212	98,469
Level 2
Liabilities:
Redeemable convertible preferred stock warrant liability		0
Level 2 | Money market funds
Assets:
Money market funds	0	0
Level 3
Liabilities:
Redeemable convertible preferred stock warrant liability		270
Level 3 | Money market funds
Assets:
Money market funds	$ 0	$ 0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details)	Sep. 21, 2020shares
Redeemable convertible preferred stock warrants
Class of Warrant or Right [Line Items]
Number of redeemable convertible preferred stock warrants converted (in shares)	32,276

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Jan. 31, 2020
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 9,038	$ 15,026
Accumulated depreciation and amortization	(5,086)	(12,033)
Property and equipment, net	3,952	2,993
Computer and hardware equipment
Property, Plant and Equipment [Line Items]
Gross property and equipment	2,147	1,954
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,213	1,129
Leasehold improvements
Property, Plant and Equipment [Line Items]
Gross property and equipment	2,292	2,120
Capitalized internal-use software
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 3,386	$ 9,823

Property and Equipment, Net - N

Property and Equipment, Net - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 400,000	$ 300,000	$ 1,000,000	$ 1,300,000
Software capitalized	400,000	1,800,000	1,500,000	4,700,000
Amortization of internal-use software	$ 200,000	$ 200,000	500,000	800,000
Impairments of internal-use software			0	$ 0
Fully amortized internal-use software written off			$ 8,000,000

Property and Equipment, Net -_2

Property and Equipment, Net - Schedule of Long-Lived Assets by Geographical Location (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Jan. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 3,952	$ 2,993
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	3,138	1,970
International
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 814	$ 1,023

Acquisitions, Intangible Asse_3

Acquisitions, Intangible Assets, and Goodwill - Narrative (Details) - USD ($)	Oct. 25, 2019	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019	Jan. 31, 2020
Business Acquisition [Line Items]
Stock-based compensation expense		$ 18,943,000	$ 9,728,000	$ 28,666,000	$ 16,561,000
Net loss		(23,926,000)	(28,619,000)	(59,708,000)	(57,621,000)
Intangible assets		20,100,000		20,100,000		$ 20,100,000
Intangible assets, accumulated amortization		7,800,000		$ 7,800,000		$ 2,700,000
Weighted average remaining useful life				2 years		2 years 8 months 12 days
Amortization expense for intangible assets		1,700,000	300,000	$ 5,100,000	600,000
Impairment for intangible assets				0	0
Impairment of goodwill				0	0
Other Acquisitions
Business Acquisition [Line Items]
Consideration					$ 1,000,000
Weighted average remaining useful life					1 year 6 months
Jask Labs Inc.
Business Acquisition [Line Items]
Purchase consideration	$ 55,100,000
Cash paid	11,200,000
Cash paid, placed in escrow	$ 900,000
Escrow term	15 months
Tax benefit related to release of valuation allowance of deferred tax assets				300,000
Acquisition-related expenses			2,600,000		$ 2,600,000
Acquisition-related costs, included as part of purchase consideration	$ 800,000
Weighted average remaining useful life	3 years
Unrecognized compensation expense related to options	$ 1,100,000
Jask Labs Inc. | Acquisition-related Expenses
Business Acquisition [Line Items]
Net loss			(3,400,000)		(3,400,000)
Jask Labs Inc. | Tax Benefit for Release of Valuation Allowance
Business Acquisition [Line Items]
Net loss			300,000		300,000
Jask Labs Inc. | Accelerated stock-based compensation
Business Acquisition [Line Items]
Net loss			$ (100,000)		(100,000)
Jask Labs Inc. | Restricted Stock
Business Acquisition [Line Items]
Stock-based compensation expense		200,000		$ 600,000
Awards granted (in shares)				130,180
Awards granted, fair value (in USD per share)				$ 12.11683
Vesting period				2 years
Unrecognized stock-based compensation		$ 800,000		$ 800,000		$ 1,400,000
Common Stock
Business Acquisition [Line Items]
Equity issued				$ 0	$ 43,873,000
Common Stock | Jask Labs Inc.
Business Acquisition [Line Items]
Equity issued	$ 43,300,000
Equity issued (in shares)	3,573,659
Equity issued, placed in escrow (in shares)	543,095
Equity issued, placed in escrow	$ 6,600,000
Option | Jask Labs Inc.
Business Acquisition [Line Items]
Equity issued	$ 600,000
Equity issued (in shares)	265,075
Equity issued and stock-based compensation expense	$ 1,700,000

Acquisitions, Intangible Asse_4

Acquisitions, Intangible Assets, and Goodwill - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Jan. 31, 2020	Oct. 25, 2019
Business Acquisition [Line Items]
Goodwill	$ 50,672	$ 50,672
Jask Labs Inc.
Business Acquisition [Line Items]
Cash			$ 782
Restricted cash			300
Accounts receivable			503
Prepaid expenses and other assets			659
Fixed assets			367
Intangible assets			17,500
Goodwill			41,368
Accounts payable			(1,760)
Deferred revenue, current			(2,358)
Accrued and other current liabilities			(1,609)
Deferred revenue, noncurrent			(354)
Other noncurrent liabilities			(291)
Total acquisition consideration			$ 55,107

Acquisitions, Intangible Asse_5

Acquisitions, Intangible Assets, and Goodwill - Pro Forma Financial Information (Details) - Jask Labs Inc. - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Oct. 31, 2019	Oct. 31, 2019
Business Acquisition [Line Items]
Revenue	$ 41,503	$ 113,124
Net loss	$ (34,258)	$ (81,025)

Acquisitions, Intangible Asse_6

Acquisitions, Intangible Assets, and Goodwill - Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Jan. 31, 2020
Business Combinations [Abstract]
Remainder of fiscal year	$ 1,648
Year one	6,148	$ 6,765
Year two	4,502	6,148
Year three		4,502
Total	$ 12,298	$ 17,415

Debt (Details)

Debt (Details) - USD ($)	1 Months Ended
	Jun. 30, 2020	Jul. 31, 2019	Jan. 31, 2020
Debt Instrument [Line Items]
Balance outstanding			$ 0
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 50,000,000
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 25,000,000
Quick ratio, minimum	1.25
Quick ratio, maximum	1.75
Line of Credit | Revolving Credit Facility | Inside of Debt Covenant Quick Ratio Threshold
Debt Instrument [Line Items]
Fixed interest rate	5.25%
Line of Credit | Revolving Credit Facility | Outside of Debt Covenant Quick Ratio Threshold
Debt Instrument [Line Items]
Fixed interest rate	4.75%
Prime Rate | Line of Credit | Revolving Credit Facility | Inside of Debt Covenant Quick Ratio Threshold
Debt Instrument [Line Items]
Basis spread on variable rate	0.75%
Prime Rate | Line of Credit | Revolving Credit Facility | Outside of Debt Covenant Quick Ratio Threshold
Debt Instrument [Line Items]
Basis spread on variable rate	0.25%
Prime Rate | Line of Credit | Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		0.25%
Prime Rate | Line of Credit | Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		0.75%

Commitment and Contingencies -

Commitment and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Oct. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2021	$ 1,199
2022	4,787
2023	4,649
2024	1,887
2024	404
Total	$ 12,926

Commitment and Contingencies _2

Commitment and Contingencies - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2020	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019	Jul. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Rent expense		$ 1	$ 0.9	$ 3	$ 2.3
Settlement amount	$ 4.5
Accrual for settlement		$ 4.5		$ 4.5
Non-cancellable purchase commitment						$ 220
Non-cancellable purchase commitment, first 18 months						90
Non-cancellable purchase commitment, year two						60
Non-cancellable purchase commitment, year three						$ 70

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 51,868	$ 40,513	$ 148,485	$ 110,745
United States
Disaggregation of Revenue [Line Items]
Total revenue	44,636	34,355	125,648	93,269
International
Disaggregation of Revenue [Line Items]
Total revenue	$ 7,232	$ 6,158	$ 22,837	$ 17,476

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019	Jan. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue recognized that was included in deferred revenue at beginning of period	$ 38,100,000	$ 29,700,000	$ 77,600,000	$ 55,900,000
Allowance for doubtful accounts for accounts receivable	100,000		100,000		$ 0
Costs capitalized during period	10,800,000	4,000,000	17,700,000	10,600,000
Amortized costs during period	2,900,000	$ 2,200,000	8,100,000	6,400,000
Impairment loss			0	$ 0
Concentration Risk [Line Items]
Allowance for doubtful accounts for accounts receivable	$ 100,000		$ 100,000		$ 0
Customer Concentration Risk | Accounts Receivable | Customer One
Concentration Risk [Line Items]
Concentration risk percentage			19.00%
Customer Concentration Risk | Accounts Receivable | Customer Two
Concentration Risk [Line Items]
Concentration risk percentage			11.00%

Revenue - Performance Obligatio

Revenue - Performance Obligation (Details) $ in Millions	Oct. 31, 2020USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation	$ 234.4
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-11-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation	$ 139.9
Performance obligation, timing	12 months

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) and Equity Incentive Plans - Narrative (Details)	Sep. 21, 2020USD ($)shares	Sep. 17, 2020periodshares	Oct. 25, 2019USD ($)$ / sharesshares	Oct. 31, 2020USD ($)planvote$ / sharesshares	Oct. 31, 2019USD ($)$ / sharesshares	Oct. 31, 2020USD ($)planvote$ / sharesshares	Oct. 31, 2019USD ($)$ / sharesshares	Jan. 31, 2020USD ($)$ / sharesshares	Jul. 31, 2020shares	Jul. 31, 2019shares	Jan. 31, 2019shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Convertible preferred stock converted into common stock (in shares) | shares	63,761,950			63,762,000		63,762,000
Convertible preferred stock converted into common stock per share (in shares) | shares	1
Convertible preferred stock converted into common stock	$ 340,200,000			$ 340,167,000		$ 340,167,000
Convertible preferred stock, shares issued (in shares) | shares				0		0
Convertible preferred stock, shares outstanding (in shares) | shares				0	63,762,000	0	63,762,000	63,762,000	63,762,000	63,762,000	53,776,000
Common stock, shares authorized (in shares) | shares				1,000,000,000		1,000,000,000		122,000,000
Common stock, par value (in USD per share) | $ / shares				$ 0.0001		$ 0.0001		$ 0.0001
Common stock, shares issued (in shares) | shares				102,000,000		102,000,000		19,000,000
Common stock, shares outstanding (in shares) | shares				102,000,000		102,000,000		19,000,000
Number of votes per share | vote				1		1
Number of plans | plan				2		2
Dividends declared (in USD per share) | $ / shares						$ 0		$ 0
Liability for early exercise of options				$ 300,000		$ 300,000		$ 400,000
Early exercise of options (in shares) | shares				91,375		91,375		139,750
Stock-based compensation expense				$ 18,943,000	$ 9,728,000	$ 28,666,000	$ 16,561,000
Accelerated stock-based compensation expense					1,600,000		1,600,000
Amount with held from employees for future purchases				600,000		600,000
Common Stock Transfers, Former Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense						300,000	1,400,000
Tender Offer, Employees and Former Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense					$ 4,800,000		$ 4,800,000
Price of shares sold (in USD per share) | $ / shares					$ 12.11683		$ 12.11683
Number of shares sold (in shares) | shares							1,686,446
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense				8,255,000	$ 5,244,000	10,883,000	$ 8,646,000
General and administrative | Tender Offer, Employees and Former Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense					2,600,000		2,600,000
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense				5,728,000	2,474,000	9,606,000	3,953,000
Research and development | Tender Offer, Employees and Former Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense					1,500,000		1,500,000
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense				4,747,000	1,960,000	7,863,000	3,866,000
Sales and marketing | Tender Offer, Employees and Former Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense					700,000		700,000
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense				213,000	50,000	$ 314,000	96,000
Cost of revenue | Tender Offer, Employees and Former Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense					$ 100,000		$ 100,000
Executive Officers
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense								$ 0
Jask Labs Inc.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to options			$ 1,100,000
Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years
Expiration period						10 years
Option, performance based | Executive Officers
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares) | shares								280,316
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares available for grant per year (in shares) | shares		2,500,000
Number of additional shares available for grant per year percentage		1.00%
Unrecognized compensation expense, period for recognition						1 year 4 months 24 days
Unrecognized stock-based compensation, excluding options				8,300,000		$ 8,300,000
Stock-based compensation expense				$ 300,000		$ 300,000
Number of shares available for issuance (in shares) | shares		2,000,000
Offering period		24 months
Number of purchase periods | period		4
Purchase period		6 months
Purchase price of common stock, percent		85.00%
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares) | shares				13,300,000		13,300,000
Number of additional shares available for grant per year (in shares) | shares				12,500,000		12,500,000
Number of additional shares available for grant per year percentage						5.00%
2010 Plan | RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accelerated stock-based compensation expense	10,900,000
2010 Plan | RSUs Subject to Performance Metrics
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accelerated stock-based compensation expense	$ 1,400,000
Jask Plans | Jask Labs Inc.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted, weighted average grant date fair value (in USD per share) | $ / shares			$ 6.39
Unrecognized compensation expense related to options				$ 300,000		$ 300,000		$ 600,000
Options granted (in shares) | shares			265,075
Options granted (in USD per share) | $ / shares			$ 9.86
Options outstanding (in shares) | shares				142,096		142,096		233,852
Options exercisable (in shares) | shares				95,079		95,079		124,184
Options exercisable (in USD per share) | $ / shares				$ 9.79		$ 9.79		$ 9.21
Options exercised (in shares) | shares						52,073
Equity Incentive Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted, weighted average grant date fair value (in USD per share) | $ / shares				$ 11.13	$ 6.68	$ 6.21	$ 5.46
Options exercised, aggregate intrinsic value				$ 17,000,000	$ 6,700,000	$ 25,900,000	$ 9,900,000
Income tax benefits recognized for stock-based compensation arrangements						0
Unrecognized compensation expense related to options				$ 40,400,000		$ 40,400,000		$ 52,000,000
Options granted (in shares) | shares						1,635,000
Options granted (in USD per share) | $ / shares						$ 12.12
Options outstanding (in shares) | shares				25,234,000		25,234,000		27,841,000
Options exercisable (in shares) | shares				15,710,000		15,710,000		14,141,000
Options exercisable (in USD per share) | $ / shares				$ 2.61		$ 2.61		$ 2.01
Options exercised (in shares) | shares						2,170,000
Equity Incentive Plans | Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense, period for recognition						2 years 7 months 6 days		3 years 1 month 6 days
Equity Incentive Plans | RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense, period for recognition						1 year 9 months 18 days
Unrecognized stock-based compensation, excluding options				$ 27,700,000		$ 27,700,000
Equity Incentive Plans | RSUs Subject to Performance Metrics
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation, excluding options				$ 1,000,000		$ 1,000,000

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) and Equity Incentive Plans - Option Activity (Details) - Equity Incentive Plans $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Oct. 31, 2020USD ($)$ / sharesshares	Jan. 31, 2020USD ($)$ / sharesshares
Number of Shares
Beginning balance (in shares) | shares	27,841
Options granted (in shares) | shares	1,635
Options exercised (in shares) | shares	(2,170)
Options cancelled (in shares) | shares	(2,072)
Ending balance (in shares) | shares	25,234	27,841
Options exercisable (in shares) | shares	15,710	14,141
Weighted Average Exercise Price
Beginning balance (in USD per share) | $ / shares	$ 3.72
Options granted (in USD per share) | $ / shares	12.12
Options exercised (in USD per share) | $ / shares	2.61
Options cancelled (in USD per share) | $ / shares	6.08
Ending balance (in USD per share) | $ / shares	4.16	$ 3.72
Options exercisable (in USD per share) | $ / shares	$ 2.61	$ 2.01
Options outstanding, weighted average remaining contractual term	7 years	7 years 8 months 12 days
Options exercisable, weighted average remaining contractual term	6 years 1 month 6 days	6 years 6 months
Options outstanding, aggregate intrinsic value | $	$ 331,066	$ 233,918
Options exercisable, aggregate intrinsic value | $	$ 230,411	$ 142,932

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) and Equity Incentive Plans - RSU Activity (Details) - RSUs - Equity Incentive Plans shares in Thousands	9 Months Ended
	Oct. 31, 2020$ / sharesshares
Number of Shares
Beginning balance (in shares)	0
Granted (in shares)	3,274
Forfeited (in shares)	(83)
Ending balance (in shares)	3,191
Weighted Average Grant Date Fair Value per Share
Granted (in USD per share) | $ / shares	$ 13.03
Forfeited (in USD per share) | $ / shares	12.12
Outstanding (in USD per share) | $ / shares	$ 13.06
Expected to vest, number of shares (in shares)	3,191
Expected to vest, weighted average grant date fair value per share (in USD per share) | $ / shares	$ 13.06

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) and Equity Incentive Plans - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 18,943	$ 9,728	$ 28,666	$ 16,561
Stock-based compensation capitalized as internal-use software costs	100	$ 200	321	$ 404
Accelerated stock-based compensation, number of shares (in shares)		172,708		172,708
Accelerated stock-based compensation expense		$ 1,600		$ 1,600
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	213	50	314	96
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	5,728	2,474	9,606	3,953
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	4,747	1,960	7,863	3,866
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 8,255	$ 5,244	$ 10,883	$ 8,646

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 417	$ 2	$ 764	$ 357

Net Loss Per Share - Calculatio

Net Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Earnings Per Share [Abstract]
Net loss	$ (23,926)	$ (28,619)	$ (59,708)	$ (57,621)
Weighted-average shares outstanding, basic and diluted (in shares)	55,816	14,650	31,044	13,953
Net loss per share, basic and diluted (in USD per share)	$ (0.43)	$ (1.95)	$ (1.92)	$ (4.13)

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	29,352	94,376	29,352	94,376
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	25,234	28,556	25,234	28,556
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	3,191	0	3,191	0
ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	44	0	44	0
Redeemable convertible preferred stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	32	32	32	32
Shares subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	166	436	166	436
Assumed options for Jask Labs acquisition
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	142	265	142	265
Issuable shares for Jask Labs acquisition
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	543	1,325	543	1,325
Redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	0	63,762	0	63,762

Uncategorized Items - sumo-2020

Label	Element	Value
Restricted Cash	us-gaap_RestrictedCash	$ 300,000
Restricted Cash	us-gaap_RestrictedCash	$ 340,000